Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07483385
Recruiting Not applicable

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07483385 · tracked via the Priya Life Science China tracker
Sponsor
The General Hospital of Western Theater Command
Phase
Not applicable
Started
2026-01-13
Last updated
2026-03-25

Condition(s) studied

Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell TransplantationHematologic Disorders

Investigational drug(s) / intervention(s)

Lusutrombopag →

Lusutrombopag: Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary.

Study summary

This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Participants must meet the following criteria: 1. The patient signed an informed consent form and voluntarily participated in the study. 2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation; 3. Age ≥18 years, regardless of gender 4. ECOG score 0-2 5. Expected survival ≥3 months 6. No severe impairment of function of major organs Exclusion Criteria: If any of the following criteria are met, the participants must be excluded from this research project: 1\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator. \-

Primary outcome measure(s)

  • Transplantation + 21-day platelet accumulation engraftment rate Description: Transplantation + 21-day platelet accumulation engraftment rate — 21 days

Trial sites (1)

FacilityCityRegionStatus
The General Hospital of the People's Liberation Army Chengdu China Recruiting

More The General Hospital of Western Theater Command trials in China

Allogeneic UCB-derived CAR-T for B-ALL Starting soon
EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT Starting soon
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL Starting soon
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia Recruiting
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07483385 on ClinicalTrials.gov ↗ ← All trials in China